Canada’s semaglutide patent wall has a crack in it, and it comes from a domestic manufacturer rather than the overseas generic houses most observers expected to move first. Apotex’s Health Canada authorization for Apo-Semaglutide Injection covers both pen configurations — the 2 mg/0.68 mg/mL and the 4 mg/1.34 mg/mL formats — making it the only generic entrant to match every commercial SKU Novo Nordisk currently offers in the Canadian market. That full SKU parity is not a minor commercial detail; it removes the formulary substitution friction that partial-format generics typically face when provincial drug plans negotiate preferred products.
The regulatory pathway here ran through Health Canada’s standard review for peptide medicines, not an abbreviated or expedited stream. That matters because semaglutide is a GLP-1 receptor agonist produced via recombinant technology, and demonstrating bioequivalence for injectable peptides carries a higher analytical burden than small-molecule generics. Apotex partnered with Orbicular Pharmaceutical Technologies, an Indian peptide-specialist firm, to meet that standard — a collaboration structure that signals the manufacturing complexity involved. No Canadian generics company had cleared this bar before. The indication is confined to type 2 diabetes and glycemic control in adults alongside diet and exercise, which mirrors Ozempic’s approved Canadian label exactly, stopping short of the cardiovascular outcomes indication and entirely excluding any weight-management use.
That last constraint defines the real clinical boundary. Wegovy — semaglutide at the 2.4 mg weekly dose — remains patent-protected, and this approval does nothing to change access for patients seeking GLP-1 therapy for obesity. Canadian prescribers writing off-label for weight loss on Ozempic will not find a cheaper legal pathway through this generic; provincial plans covering diabetes indications will. The immediate beneficiaries are patients with type 2 diabetes on public drug plans where generic substitution is automatic once a product is listed, potentially triggering significant reimbursement savings across provinces that have struggled with Ozempic’s list price.
Apotex has not announced a commercial launch date beyond “very near future,” which leaves the critical variable unresolved. Provincial formulary listing decisions — not the Health Canada authorization itself — determine actual patient access and price competition. Watch for British Columbia’s PharmaCare and Ontario’s ODB formulary committees: their listing timelines and negotiated generic prices will set the national reference point for every provincial plan that follows.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
